Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7031674 | 0.87 | HTR2A (0.47) | HTR2AHTR2CTMEM97HTR7HTR6 | |
| SCHEMBL7026004 | 0.85 | HTR2A (0.45) | HTR2AHTR2CTMEM97HTR7HTR6 | |
| SCHEMBL7029662 | 0.84 | HTR2A (0.53) | HTR2AHTR2CDRD2ADRA2BDRD1 | |
| SCHEMBL7026063 | 0.84 | HTR2A (0.49) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7026722 | 0.83 | OPRM1 (0.47) | HTR2AHTR2CKCNH2TMEM97HTR7 | |
| SCHEMBL7033457 | 0.83 | HTR2A (0.48) | HTR2AHTR2CHTR7PABPC1HTR6 | |
| SCHEMBL7023032 | 0.80 | HTR2A (0.49) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7030736 | 0.79 | HTR2A (0.46) | HTR2AHTR2CKCNH2HTR7HTR6 | |
| SCHEMBL7027090 | 0.78 | HTR2A (0.52) | HTR2AHTR2CKCNH2HTR7HTR6 | |
| SCHEMBL7027799 | 0.78 | HTR2A (0.47) | HTR2AHTR2CKCNH2HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | MERCK PATENT GMBH (DE) | 2003-07-10 | — | — | US | disclosed |
| CN-1394203-A | As 5-HT2APiperidine and piperazine derivatives of receptor antagonists | MERCK PATENT GMBH (DE) | 2003-01-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | HTR2A, HTR1A, HTR5A | HTR2A 1/4885HTR2C 5/4885DRD2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.